Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.54 |
| ▸ | F9 | P00740 | 2/20 | 0.44 |
| ▸ | F12 | P00748 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | PLAT | P00750 | 2/20 | 0.44 |
| ▸ | F11 | P03951 | 2/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.44 |
| ▸ | F7 | P08709 | 2/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.44 |
| ▸ | CTRL | P40313 | 2/20 | 0.44 |
| ▸ | CTRB2 | Q6GPI1 | 2/20 | 0.44 |
| ▸ | CTRC | Q99895 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13401736 | 0.80 | F10 (0.59) | F10F9F12PLAUPLAT | |
| SCHEMBL22944436 | 0.69 | F10 (0.62) | F10F9F12PLAUPLAT | |
| SCHEMBL13242208 | 0.69 | F10 (0.77) | F10 | |
| SCHEMBL19782045 | 0.65 | L3MBTL1 (0.58) | F10 | |
| SCHEMBL26997149 | 0.63 | F10 (0.60) | F10F9F12PLAUPLAT | |
| SCHEMBL25670613 | 0.62 | F10 (0.37) | F10 | |
| SCHEMBL5892382 | 0.61 | ALDH1A1 (0.42) | — | |
| SCHEMBL9118957 | 0.59 | F10 (0.40) | F10 | |
| SCHEMBL22922212 | 0.59 | F10 (0.78) | F10 | |
| SCHEMBL13436741 | 0.59 | F10 (0.78) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | GEUNS JOANNES | 2010-04-22 | — | — | US | disclosed |
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | GEUNS JOANNES | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | SORD, CASP3, TXNRD2 | F10 551/4885F9 1886/4885F12 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.